Simvastatin

證據等級: L5

預測適應症: 8 個

Simvastatin: From Hypercholesterolemia to Familial Hypercholesterolemia

One-Sentence Summary

Simvastatin is a well-established HMG-CoA reductase inhibitor (statin), classically used for hypercholesterolemia and cardiovascular risk reduction. The TxGNN model predicts it may be effective for Familial Hypercholesterolemia (FH), with 19 clinical trials and 18 publications currently supporting this direction — though this reflects existing standard-of-care use rather than a genuinely novel signal.

Quick Overview

Item	Content
Original Indication	Not available in source data (Fimea license records absent; drug not marketed in Finland). Simvastatin is generically known as a statin used for hypercholesterolemia/dyslipidemia.
Predicted New Indication	Familial Hypercholesterolemia
TxGNN Prediction Score	99.63%
Evidence Level	L1
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured MOA data (original_moa) is marked as a data gap, but the evidence pack's repurposing rationale supplies the mechanistic story directly: simvastatin inhibits HMG-CoA reductase, lowering hepatic cholesterol synthesis and up-regulating LDL receptor expression, which increases LDL-C clearance from plasma.

Familial Hypercholesterolemia (FH) — and its genetic-nomenclature equivalent "autosomal dominant hypercholesterolemia" (independently predicted at rank 4, also scored L1) — is caused by defective LDL receptor pathway function, leading to impaired LDL clearance. Statin-driven LDL receptor up-regulation maps directly onto this disease mechanism, which is why simvastatin (and statins generally) are already first-line standard therapy for FH, including pediatric and heterozygous populations.

Because of this direct mechanistic fit, the evidence pack itself flags this as a textbook-level mechanism–indication pairing rather than a novel discovery from the TxGNN model — the two independent high-scoring predictions (FH and its genetic synonym) corroborate each other but do not represent new clinical insight.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00552097	Phase 3	Completed	720	ENHANCE trial: ezetimibe + high-dose simvastatin vs. simvastatin alone on carotid atherosclerosis progression in HeFH
NCT00129402	Phase 3	Completed	248	Ezetimibe + simvastatin efficacy/safety/tolerability in adolescents with HeFH
NCT03884452	Phase 3	Completed	50	Ezetimibe added to atorvastatin or simvastatin in homozygous FH (HoFH)
NCT03885921	Phase 3	Completed	44	Long-term open-label extension of above HoFH ezetimibe + statin study
NCT00654446	Phase 3	Completed	442	Renal effects of rosuvastatin vs. simvastatin in FH/dyslipidaemia patients
NCT00465088	Phase 3	Completed	199	Niacin ER + simvastatin vs. atorvastatin lipid effects in hyperlipidemia
NCT00145574	Phase 4	Completed	194	Colesevelam add-on to stable statin therapy (incl. simvastatin) in pediatric HeFH
NCT01709500	Phase 3	Completed	249	Alirocumab vs. placebo in HeFH not controlled on background lipid-modifying therapy (incl. statins)
NCT01623115	Phase 3	Completed	486	Alirocumab vs. placebo in HeFH not controlled on background lipid-modifying therapy (incl. statins)
NCT01070966	N/A	Completed	2089	Post-marketing re-examination of VYTORIN (ezetimibe/simvastatin) safety and efficacy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41824552	2026	Guideline	Circulation	2026 ACC/AHA dyslipidemia guideline replacing 2018 blood cholesterol guideline; statins remain foundational therapy
18376000	2008	RCT	New England Journal of Medicine	ENHANCE trial: simvastatin ± ezetimibe effect on atherosclerosis progression in FH
31696945	2019	Review (Cochrane)	Cochrane Database of Systematic Reviews	Systematic review of statins for children with FH
15794711	2005	Review	Expert Opinion on Drug Safety	Benefits/risks assessment of simvastatin in FH
27417002	2016	Cohort	Journal of the American College of Cardiology	Statin treatment reduces CAD events and mortality in heterozygous FH
35629051	2022	Cohort	Journal of Clinical Medicine	Cellular immunity parameters in children with FH treated with simvastatin
35361995	2022	Cohort	The Pharmacogenomics Journal	Combined FH and statin pharmacogenomic NGS testing strategy
12908847	2003	Review	Drug Safety	Benefits and risks of simvastatin in patients with FH
21173733	2010	RCT	International Angiology	Long-term efficacy/safety of ezetimibe/simvastatin in FH
11383320	2001	RCT	Nutrition, Metabolism and Cardiovascular Diseases	Atorvastatin vs. simvastatin for LDL-C goal attainment in HeFH

Finland Market Information

Simvastatin currently has no registered market authorizations in Finland (market_status: 未上市, total_licenses: 0) in the evidence pack — no license records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The FH indication is backed by L1-level evidence (19 trials including the landmark ENHANCE RCT, 18 publications including Cochrane reviews and a 2026 ACC/AHA guideline), and is reinforced by an independent, equally L1-scored prediction for the same disease under its genetic name ("autosomal dominant hypercholesterolemia"). However, this reflects simvastatin's existing role as standard-of-care therapy rather than a novel repurposing signal, and two blocking/high-severity data gaps remain unresolved.

To proceed, the following is needed:

TFDA/Fimea package insert warnings and contraindications (DG001, blocking — currently missing entirely)
Documented mechanism of action from DrugBank (DG002)
Clarification of Finland market/registration status, since the drug currently shows zero licenses despite being a globally marketed generic
Reconciliation of the FH vs. autosomal-dominant-hypercholesterolemia predictions as a single indication rather than two separate candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.